A first look [BE/BA News]

posted by BRB  – Canada, 2022-12-02 19:20 (671 d 15:01 ago) – Posting: # 23379
Views: 7,838

Hi J,
No, it's still there. See lines 260-261:

The number of evaluable subjects in a PK BE study should not be less than 12. For highly variable drug products, a minimum of 24 subjects are recommended for BE assessment.

❝ Almost a complete overhaul. Very detailed. I notice something, they removed the min sample size requirement of n=12 (Unless it's written in later part of the doc)


Complete thread:

UA Flag
Activity
 Admin contact
23,240 posts in 4,884 threads, 1,653 registered users;
64 visitors (0 registered, 64 guests [including 9 identified bots]).
Forum time: 11:22 CEST (Europe/Vienna)

[The] impatience with ambiguity can be criticized in the phrase:
absence of evidence is not evidence of absence.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5